Extended Data Table 1 Survival outcomes in the safety analysis set

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

  1. aOne patient was missing a value for CLDN18.2 expression.
  2. bDefined as ≥75% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining as determined by central IHC.
  3. cDefined as ≥50% but <75% of tumor cells demonstrating moderate-to-strong membranous CLDN18 staining as determined by central IHC.
  4. Efficacy was assessed as an exploratory analysis in cohort 4 A + 4B.
  5. CI, confidence interval; CLDN18, claudin 18; CLDN18.2, claudin 18 isoform 2; IHC, immunohistochemistry; NE, not estimable; OS, overall survival; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.
Back to article page